These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37646668)

  • 1. Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia.
    Ingelman-Sundberg HM; Blixt L; Wullimann D; Wu J; Gao Y; Healy K; Muschiol S; Bogdanovic G; Åberg M; Kjellander C; Grifoni A; Sette A; Aleman S; Chen P; Blennow O; Hansson L; Ljunggren HG; Chen MS; Buggert M; Österborg A
    Haematologica; 2024 Feb; 109(2):646-651. PubMed ID: 37646668
    [No Abstract]   [Full Text] [Related]  

  • 2. Unexpected kinetics of anti-SARS-CoV-2 total antibodies in two patients with chronic lymphocytic leukemia.
    Favresse J; Eucher C; Elsen M; Graux C; Goebels P; Laffineur K; Nicolas JB; Dogné JM; Douxfils J
    Br J Haematol; 2020 Aug; 190(4):e187-e189. PubMed ID: 32557555
    [No Abstract]   [Full Text] [Related]  

  • 3. An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.
    Vesin B; Lopez J; Noirat A; Authié P; Fert I; Le Chevalier F; Moncoq F; Nemirov K; Blanc C; Planchais C; Mouquet H; Guinet F; Hardy D; Vives FL; Gerke C; Anna F; Bourgine M; Majlessi L; Charneau P
    Mol Ther; 2022 Sep; 30(9):2984-2997. PubMed ID: 35484842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preexisting immunity restricts mucosal antibody recognition of SARS-CoV-2 and Fc profiles during breakthrough infections.
    Selva KJ; Ramanathan P; Haycroft ER; Reynaldi A; Cromer D; Tan CW; Wang LF; Wines BD; Hogarth PM; Downie LE; Davis SK; Purcell RA; Kent HE; Juno JA; Wheatley AK; Davenport MP; Kent SJ; Chung AW
    JCI Insight; 2023 Sep; 8(18):. PubMed ID: 37737263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional humoral and cellular response of monovalent COVID-19-vaccines against Omicron BA.2 variant of SARS-CoV-2 in patients with chronic lymphocytic leukemia.
    Passerini M; Ratishvili T; Monroe JM; Temesgen Z; Witzig TE; Kay NE; Kennedy RB; Parikh SA
    Leuk Lymphoma; 2023 Apr; 64(4):874-883. PubMed ID: 36908110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia.
    Mellinghoff SC; Mayer L; Robrecht S; Weskamm LM; Dahlke C; Gruell H; Schlotz M; Vanshylla K; Schloser HA; Thelen M; Fink AM; Fischer K; Klein F; Addo MM; Eichhorst B; Hallek M; Langerbeins P
    Haematologica; 2022 Oct; 107(10):2480-2484. PubMed ID: 35734927
    [No Abstract]   [Full Text] [Related]  

  • 7. T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial.
    Blixt L; Wullimann D; Aleman S; Lundin J; Chen P; Gao Y; Cuapio A; Akber M; Lange J; Rivera-Ballesteros O; Buggert M; Ljunggren HG; Hansson L; Österborg A
    Haematologica; 2022 Apr; 107(4):1000-1003. PubMed ID: 35045694
    [No Abstract]   [Full Text] [Related]  

  • 8. SARS-CoV-2 convalescence and hybrid immunity elicits mucosal immune responses.
    Puhach O; Bellon M; Adea K; Bekliz M; Hosszu-Fellous K; Sattonnet P; Hulo N; Kaiser L; Eckerle I; Meyer B
    EBioMedicine; 2023 Dec; 98():104893. PubMed ID: 38035462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia patients during the Omicron outbreak.
    Kohn M; Alsuliman T; Lamure S; Cheminant M; Delage J; Merle De Boever C; Tudesq JJ; Marjanovic Z; Van de Wyngaert Z; Malard F; Brissot E; Rigaudeau S; Marque-Juillet S; Therby A; Cartron G; Rousselot P; Hermine O; Duléry R; Besson C
    Leuk Lymphoma; 2022 Nov; 63(11):2686-2690. PubMed ID: 35719107
    [No Abstract]   [Full Text] [Related]  

  • 10. Improved outcomes in patients with chronic lymphocytic leukaemia infected during the omicron BA.5 subvariant surge.
    Bronstein Y; Levi S; Herishanu Y
    Br J Haematol; 2023 Jun; 201(6):1125-1128. PubMed ID: 37042235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal vaccines for SARS-CoV-2: triumph of hope over experience.
    Pilapitiya D; Wheatley AK; Tan HX
    EBioMedicine; 2023 Jun; 92():104585. PubMed ID: 37146404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes.
    Guo W; Zheng Y; Feng S
    Front Cell Infect Microbiol; 2023; 13():1207225. PubMed ID: 37928188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination.
    Blixt L; Gao Y; Wullimann D; Murén Ingelman-Sundberg H; Muschiol S; Healy K; Bogdanovic G; Pin E; Nilsson P; Kjellander C; Grifoni A; Sette A; Sällberg Chen M; Ljunggren HG; Buggert M; Hansson L; Österborg A
    Blood; 2022 Dec; 140(22):2403-2407. PubMed ID: 36150168
    [No Abstract]   [Full Text] [Related]  

  • 14. mRNA COVID-19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta-analysis.
    Molica S; Giannarelli D; Montserrat E
    Eur J Haematol; 2022 Mar; 108(3):264-267. PubMed ID: 34856031
    [No Abstract]   [Full Text] [Related]  

  • 15. Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
    Chang A; Akhtar A; Linderman SL; Lai L; Orellana-Noia VM; Valanparambil R; Ahmed H; Zarnitsyna VI; McCook-Veal AA; Switchenko JM; Koff JL; Blum KA; Ayers AA; O'Leary CB; Churnetski MC; Sulaiman S; Kives M; Sheng P; Davis CW; Nooka AK; Antia R; Dhodapkar MV; Suthar MS; Cohen JB; Ahmed R
    J Clin Oncol; 2022 Sep; 40(26):3020-3031. PubMed ID: 35436146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence.
    Focosi D; Maggi F; Casadevall A
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
    Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
    mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia.
    Herishanu Y; Avivi I; Levi S; Shefer G; Bronstein Y; Moshiashvili MM; Ziv T; Scarfò L; Perry C; Ghia P
    Blood Adv; 2022 Jan; 6(1):148-151. PubMed ID: 34614513
    [No Abstract]   [Full Text] [Related]  

  • 19. Plasma metabolomic characterization of SARS-CoV-2 Omicron infection.
    Li X; Liu Y; Xu G; Xie Y; Wang X; Wu J; Chen H
    Cell Death Dis; 2023 Apr; 14(4):276. PubMed ID: 37076483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic.
    Arellano-Llamas AA; Vela-Ojeda J; Hernandez-Caballero A
    Curr Oncol Rep; 2022 Feb; 24(2):209-213. PubMed ID: 35061199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.